Mesa Laboratories (MLAB) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.30
- Estimate
- $2.55
- Surprise
- -49.1%
- Revenue (period 2026-06-30)
- $60.1M
- Score at report (before → after)
- 5.4 → 5.3/10
Revenue source: xbrl.
How the report landed
Mesa Laboratories (MLAB) missed the $2.55 estimate with adjusted EPS of $1.30 — a large 49.1% shortfall. TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.3/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MLAB Hold at 5.3/10.
3 of the last 4 quarters beat the estimate; this quarter's -49.1% surprise compares with a +9.4% four-quarter average. Next scheduled report: 2026-11-09.
What supports the rating
- Strong earnings beat streak (3/4)
- Earnings estimates trending UP
What argues against it
- Concentration risk — Product: Clinical Genomics consumables (80.0%)
- Analyst target reached - limited upside remaining
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $131.32
- Stop
- $122.88
The stock trades at 154.5× trailing but 12.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
MLAB at TrendMatrix's latest read
Technology names get repriced on forward expectations more than trailing prints — a quarter here is read through next-year growth and multiple, not the EPS line alone.
- Industry
- Scientific & Technical Instruments
- Market cap
- $734.8M
- P/E (fwd)
- 12.8
- P/E (ttm)
- 154.5
- 52-week range
- $69.51–$144.35
- Off 52-week high
- 9.0%
- RSI (14)
- 62
- Volume vs avg
- 1.51×
- Score today
- 5.3/10